{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:23:57Z","timestamp":1780100637597,"version":"3.54.0"},"reference-count":58,"publisher":"Walter de Gruyter GmbH","issue":"0","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,3,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n<jats:sec id=\"j_dmpt-2020-0101_s_999\">\n<jats:title id=\"d54116195e200\">Background<\/jats:title>\n<jats:p>Evidence from the literature, highlights the increased risk of developing glucose intolerance and type 2 diabetes mellitus (T2DM) with statin therapy. In addition, few animal studies demonstrate that adipsin secreted from adipocytes plays a crucial role in insulin secretion and the development of T2DM.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"j_dmpt-2020-0101_s_998\">\n<jats:title id=\"d54116195e207\">Methods<\/jats:title>\n<jats:p>To further explore the role of serum adipsin, in this prospective open label study, 55 newly diagnosed dyslipidemic patients were enrolled. Before starting statin therapy, liver function test (LFT), kidney function test (KFT), lipid profile, glycemic parameters [glycated hemoglobin A (HbA<jats:sub>1c<\/jats:sub>), fasting blood sugar (FBS), and postprandial blood sugar (PPBS)], serum insulin, and serum adipsin were estimated. Then these patients were prescribed statin (i.e. atorvastatin, rosuvastatin, or pitavastatin) and after 12 weeks of therapy, all the above investigations were repeated.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"j_dmpt-2020-0101_s_997\">\n<jats:title id=\"d54116195e217\">Results<\/jats:title>\n<jats:p>After 12 weeks of statin therapy, the LFT and KFT values remained unchanged and lipid parameters showed significant improvement. But the glycemic parameters deranged significantly (p &lt; 0.001), i.e. FBS, PPBS, and HbA<jats:sub>1c<\/jats:sub> increased by 12.49% (102.99 \u00b1 20.76 mg\/dL), 24.72% (147.71 \u00b1 47.29 mg\/dL), and 21.43% (6.38 \u00b1 1.34%), respectively. On the other hand, the baseline adipsin (2.73 \u00b1 1.99 ng\/mL) and insulin (16.13 \u00b1 12.50 mIU\/L) levels reduced significantly (p &lt; 0.0001) to 1.43 \u00b11.13 ng\/mL and 6.91 \u00b1 5.93 mIU\/L, respectively. The reduction in serum adipsin also showed a positive correlation with reduction in serum insulin (<jats:italic>r<\/jats:italic> = 0.85; p &lt; 0.0001). None of the patients experienced any significant adverse effect or reaction leading to discontinuation of therapy.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"j_dmpt-2020-0101_s_996\">\n<jats:title id=\"d54116195e229\">Conclusions<\/jats:title>\n<jats:p>There might be an association between reduction in adipsin and development of glucose intolerance by statin therapy.<\/jats:p>\n<\/jats:sec>","DOI":"10.1515\/dmpt-2020-0101","type":"journal-article","created":{"date-parts":[[2020,3,31]],"date-time":"2020-03-31T14:11:44Z","timestamp":1585663904000},"source":"Crossref","is-referenced-by-count":2,"title":["Exploring the role of adipsin in statin-induced glucose intolerance: a prospective open label study"],"prefix":"10.1515","volume":"0","author":[{"given":"Jahnavi","family":"Maini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harmeet Singh","family":"Rehan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhur","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lalit Kumar","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","reference":[{"key":"ref481","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1007\/s00125-006-0269-5","article-title":"Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control","volume":"49","year":"2006","journal-title":"Diabetologia"},{"key":"ref321","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1016\/j.jacc.2006.04.026","article-title":"AHA\/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update","volume":"47","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1365-2796.2005.01453.x","article-title":"Risk for fatal statin-induced rhabdomyolysis as a consequence of misinterpretation of \u2019evidence-based medicine\u2019","volume":"257","year":"2005","journal-title":"J Intern Med"},{"key":"ref451","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1002\/pds.4020","article-title":"Statin use and the risk of developing diabetes: a network meta-analysis","volume":"25","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1212\/WNL.58.9.1333","article-title":"Statins and risk of polyneuropathy: a case-control study","volume":"58","year":"2002","journal-title":"Neurology"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.amjmed.2004.07.041","article-title":"Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults","volume":"117","year":"2004","journal-title":"Am J Med"},{"key":"ref491","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.cell.2014.06.005","article-title":"Adipsin is an adipokine that improves \u03b2 cell function in diabetes","volume":"158","year":"2014","journal-title":"Cell"},{"key":"ref471","doi-asserted-by":"crossref","first-page":"111","DOI":"10.5551\/jat.12.111","article-title":"Reduction of serum ubiquinol-10 and ubiquinone-10 levels by atorvastatin in hypercholesterolemic patients","volume":"12","year":"2005","journal-title":"J Atheroscler Thromb"},{"key":"ref301","first-page":"FC04","article-title":"Effect of atorvastatin on glycaemic parameters in normoglycaemic and prediabetic subjects: a prospective, panel study","volume":"11","year":"2017","journal-title":"J Clin Diagn Res"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1007\/BF02088142","article-title":"Acute hepatitis induced by HMG-CoA reductase inhibitor, lovastatin","volume":"39","year":"1994","journal-title":"Digest Dis Sci"},{"key":"ref391","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.amjmed.2004.07.041","article-title":"Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults","volume":"117","year":"2004","journal-title":"Am J Med"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/S0140-6736(09)60447-5","article-title":"Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial","volume":"373","year":"2009","journal-title":"Lancet"},{"key":"ref291","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.atherosclerosis.2015.06.001","article-title":"Effect of pitavastatin on glucose, HbA1c and incident diabetes: A meta-analysis of randomized controlled clinical trials in individuals without diabetes","volume":"241","year":"2015","journal-title":"Atherosclerosis"},{"key":"ref221","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","article-title":"Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"ref01","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1016\/j.jacc.2006.04.026","article-title":"AHA\/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update","volume":"47","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"ref611","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.atherosclerosis.2015.06.001","article-title":"Effect of pitavastatin on glucose, HbA1c and incident diabetes: A meta-analysis of randomized controlled clinical trials in individuals without diabetes","volume":"241","year":"2015","journal-title":"Atherosclerosis"},{"key":"ref431","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials","volume":"375","year":"2010","journal-title":"Lancet"},{"key":"ref521","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1161\/01.cir.0000437738.63853.7a","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults","volume":"129","year":"2014","journal-title":"Circulation"},{"key":"ref331","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jacc.2004.07.001","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines","volume":"44","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"ref281","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(03)13636-7","article-title":"Heart Protection Study Collaborative Group. MRC\/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial","volume":"361","year":"2003","journal-title":"Lancet"},{"key":"ref311","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1161\/CIR.0b013e318235eb4d","article-title":"AHA\/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation","volume":"124","year":"2011","journal-title":"Circulation"},{"key":"ref411","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1080\/14656566.2016.1220539","article-title":"Statins worsen glycemic control of T2DM in target LDL-c level and LDL-c reduction dependent manners: a meta-analysis","volume":"17","year":"2016","journal-title":"Expert Opin Pharmacother"},{"key":"ref401","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/S0140-6736(09)60447-5","article-title":"Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial","volume":"373","year":"2009","journal-title":"Lancet"},{"key":"ref631","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1161\/CIR.0b013e318235eb4d","article-title":"AHA\/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation","volume":"124","year":"2011","journal-title":"Circulation"},{"key":"ref511","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/S0140-6736(15)60336-1","article-title":"Pleiotropic effects of statins in hypercholesterolaemia: a prospective observational study using a lipoproteomic based approach","volume":"385","year":"2015","journal-title":"Lancet"},{"key":"ref591","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1161\/01.CIR.103.3.357","article-title":"Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study","volume":"103","year":"2001","journal-title":"Circulation"},{"key":"ref251","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS. Air Force\/Texas Coronary Atherosclerosis Prevention Study","volume":"279","year":"1998","journal-title":"J Am Med Assoc"},{"key":"ref361","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1365-2796.2005.01453.x","article-title":"Risk for fatal statin-induced rhabdomyolysis as a consequence of misinterpretation of \u2019evidence-based medicine\u2019","volume":"257","year":"2005","journal-title":"J Intern Med"},{"key":"ref541","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","article-title":"Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"ref621","first-page":"FC04","article-title":"Effect of atorvastatin on glycaemic parameters in normoglycaemic and prediabetic subjects: a prospective, panel study","volume":"11","year":"2017","journal-title":"J Clin Diagn Res"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials","volume":"375","year":"2010","journal-title":"Lancet"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1007\/s00125-006-0269-5","article-title":"Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control","volume":"49","year":"2006","journal-title":"Diabetologia"},{"key":"ref191","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/S0140-6736(15)60336-1","article-title":"Pleiotropic effects of statins in hypercholesterolaemia: a prospective observational study using a lipoproteomic based approach","volume":"385","year":"2015","journal-title":"Lancet"},{"key":"ref601","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(03)13636-7","article-title":"Heart Protection Study Collaborative Group. MRC\/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial","volume":"361","year":"2003","journal-title":"Lancet"},{"key":"ref341","doi-asserted-by":"crossref","first-page":"53E","DOI":"10.1016\/j.amjcard.2005.06.006","article-title":"Recent National Cholesterol Education Program Adult Treatment Panel III update: adjustments and options","volume":"96","year":"2005","journal-title":"Am J Cardiol"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1080\/14656566.2016.1220539","article-title":"Statins worsen glycemic control of T2DM in target LDL-c level and LDL-c reduction dependent manners: a meta-analysis","volume":"17","year":"2016","journal-title":"Expert Opin Pharmacother"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jacc.2004.07.001","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines","volume":"44","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"111","DOI":"10.5551\/jat.12.111","article-title":"Reduction of serum ubiquinol-10 and ubiquinone-10 levels by atorvastatin in hypercholesterolemic patients","volume":"12","year":"2005","journal-title":"J Atheroscler Thromb"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/sj.bjp.0702397","article-title":"Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet \u03b2-cells","volume":"126","year":"1999","journal-title":"Br J Pharmacol"},{"key":"ref381","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1007\/BF02088142","article-title":"Acute hepatitis induced by HMG-CoA reductase inhibitor, lovastatin","volume":"39","year":"1994","journal-title":"Digest Dis Sci"},{"key":"ref201","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1161\/01.cir.0000437738.63853.7a","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults","volume":"129","year":"2014","journal-title":"Circulation"},{"key":"ref231","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1056\/NEJMoa0706201","article-title":"Rosuvastatin in older patients with systolic heart failure","volume":"357","year":"2007","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"53E","DOI":"10.1016\/j.amjcard.2005.06.006","article-title":"Recent National Cholesterol Education Program Adult Treatment Panel III update: adjustments and options","volume":"96","year":"2005","journal-title":"Am J Cardiol"},{"key":"ref421","doi-asserted-by":"crossref","first-page":"39982","DOI":"10.1038\/srep39982","article-title":"Association between reductions in low-density lipoprotein cholesterol with statin therapy and the risk of new-onset diabetes: a meta-analysis","volume":"7","year":"2017","journal-title":"Sci Rep"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1001\/jama.2011.860","article-title":"Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis","volume":"305","year":"2011","journal-title":"J Am Med Assoc"},{"key":"ref461","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/sj.bjp.0702397","article-title":"Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet \u03b2-cells","volume":"126","year":"1999","journal-title":"Br J Pharmacol"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1002\/pds.4020","article-title":"Statin use and the risk of developing diabetes: a network meta-analysis","volume":"25","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref531","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.2337\/diacare.26.10.2713","article-title":"Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial","volume":"26","year":"2003","journal-title":"Diabetes Care"},{"key":"ref551","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1056\/NEJMoa0706201","article-title":"Rosuvastatin in older patients with systolic heart failure","volume":"357","year":"2007","journal-title":"N Engl J Med"},{"key":"ref441","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1001\/jama.2011.860","article-title":"Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis","volume":"305","year":"2011","journal-title":"J Am Med Assoc"},{"key":"ref501","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/sj.bjp.0707250","article-title":"Anti-adipogenic action of pitavastatin occurs through the coordinate regulation of PPAR gamma and Pref-1 expression","volume":"151","year":"2007","journal-title":"Br J Pharmacol"},{"key":"ref371","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1212\/WNL.58.9.1333","article-title":"Statins and risk of polyneuropathy: a case-control study","volume":"58","year":"2002","journal-title":"Neurology"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"39982","DOI":"10.1038\/srep39982","article-title":"Association between reductions in low-density lipoprotein cholesterol with statin therapy and the risk of new-onset diabetes: a meta-analysis","volume":"7","year":"2017","journal-title":"Sci Rep"},{"key":"ref171","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.cell.2014.06.005","article-title":"Adipsin is an adipokine that improves \u03b2 cell function in diabetes","volume":"158","year":"2014","journal-title":"Cell"},{"key":"ref211","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.2337\/diacare.26.10.2713","article-title":"Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial","volume":"26","year":"2003","journal-title":"Diabetes Care"},{"key":"ref271","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1161\/01.CIR.103.3.357","article-title":"Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study","volume":"103","year":"2001","journal-title":"Circulation"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/sj.bjp.0707250","article-title":"Anti-adipogenic action of pitavastatin occurs through the coordinate regulation of PPAR gamma and Pref-1 expression","volume":"151","year":"2007","journal-title":"Br J Pharmacol"},{"key":"ref571","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS. Air Force\/Texas Coronary Atherosclerosis Prevention Study","volume":"279","year":"1998","journal-title":"J Am Med Assoc"}],"container-title":["Drug Metabolism and Personalized Therapy"],"original-title":[],"link":[{"URL":"http:\/\/www.degruyter.com\/view\/j\/dmdi.ahead-of-print\/dmpt-2020-0101\/dmpt-2020-0101.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/dmpt-2020-0101\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T21:52:30Z","timestamp":1619041950000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/dmpt-2020-0101\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,27]]},"references-count":58,"journal-issue":{"issue":"0"},"URL":"https:\/\/doi.org\/10.1515\/dmpt-2020-0101","relation":{},"ISSN":["2363-8915"],"issn-type":[{"value":"2363-8915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,27]]}}}